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After the manufacture of Lyme vaccine was discontin-
ued in 2002, strategies to prevent Lyme disease (LD) have 
focused on personal protective measures. Effectiveness of 
these measures has not been conclusively demonstrated. 
The aim of our case–control study was to assess the ef-
fectiveness of personal preventive measures in a highly dis-
ease-endemic area. Case-patients were persons with LD 
reported to Connecticut’s Department of Public Health and 
classiﬁ  ed as having deﬁ  nite, possible, or unlikely LD. Age-
matched controls without LD were identiﬁ  ed. Study partici-
pants were interviewed to assess the practice of preventive 
measures and to obtain information on occupational and 
recreational risk factors. Use of protective clothing was 40% 
effective; routine use of tick repellents on skin or clothing 
was 20% effective. Checking one’s body for ticks and spray-
ing property with acaricides were not effective. We conclud-
ed that use of protective clothing and of tick repellents (on 
skin or clothing) are effective in preventing LD.
L
yme disease (LD) is the most commonly reported 
tick-borne illness in the United States (1,2). A vaccine 
against the disease was licensed in 1998 for use in persons 
15–70 years of age (3). However, because of poor sales, it 
was withdrawn from the market in 2002. Recommendations 
for preventing LD currently focus on personal protective 
measures and interventions to reduce abundance of vector 
ticks (4). Strategies include avoidance of tick-infested ar-
eas, use of protective clothing (i.e., wearing long-sleeved 
shirts and long pants, which decrease the area of exposed 
skin), routine checks of one’s body for ticks, and the use of 
tick repellents on either the skin or clothing. Other strate-
gies have targeted the environment and vertebrate hosts of 
deer ticks; however, such approaches are often impractical, 
and their effects on the incidence of LD are unknown. Fi-
nally, use of antimicrobial prophylaxis in selected persons 
who have been bitten by a deer tick may be effective (5).
Although personal protective measures are frequently 
recommended by medical providers, public health ofﬁ  cials, 
and the lay press in areas where the disease is endemic, 
few data about their effectiveness exist. In 1992, Her-
rington et al. (6) found that self-perceived risk of acquir-
ing LD and knowledge about the disease correlated with 
the use of personal protective measures; however, even in 
highly LD-endemic areas such as Connecticut, adherence 
to these personal protective measures varied greatly—only 
79% of respondents routinely used tick repellents and 93% 
reported inspecting themselves for and removing ticks af-
ter being outdoors. In 2001, Phillips et al. found that 80% 
of the surveyed residents of Nantucket reported checking 
their bodies for ticks after potential tick exposures, 53% 
used protective clothing (such as wearing long pants and 
long-sleeved shirts), 34% reported routinely avoiding tick 
infested areas, and 11% reported routine use of tick repel-
lents (7). These researchers did not ﬁ  nd a difference in re-
ported frequency of LD among those who did and those 
who did not report preventive behavior. Similarly, Orloski 
et al. did not ﬁ  nd any statistically signiﬁ  cant differences in 
use of protective measures between persons with LD and 
age-matched controls (8).
Although certain occupations, such as working out-
doors in forestry or landscaping, have been suggested to 
increase the risk for LD, few studies document increased 
risk among such workers. Smith et al. evaluated outdoor 
workers by using questionnaires and serologic tests for an-
tibody to Borrelia burgdorferi and found that workers with 
a history of outdoor employment were twice as likely to 
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be seropositive as those without such a history; however, 
this difference was not statistically signiﬁ  cant (9). A study 
conducted in California by Lane et al. found that outdoor 
occupations such as woodcutting were associated with an 
increased risk for LD (10).
We conducted a matched case–control study of per-
sons 15–70 years of age residing in Connecticut. The pur-
pose was to assess the effectiveness of Lyme vaccine and 
personal protective measures against LD. The study ceased 
soon after Lyme vaccine was withdrawn from the market.
Methods
Study Population
We conducted a matched case–control study from July 
2000 to February 2003. Study participants were identiﬁ  ed 
through an active surveillance system for LD initiated in 
1991. Physicians in private practice and other health main-
tenance organizations throughout the state participated in 
the surveillance system. Staff of the State of Connecticut 
Department of Public Health (CT-DPH) contacted health-
care providers regularly to inquire about newly diagnosed 
cases of LD. Supplemental follow-up reporting forms were 
also sent to physicians when additional clinical informa-
tion was needed. The study was approved by the Human 
Investigations Committee at the Yale University School of 
Medicine and the Institutional Review Boards of the CT-
DPH and the Centers for Disease Control and Prevention 
(CDC).
Potential case-patients were persons 15–70 years of 
age (because Lyme vaccine was approved for persons in 
this age range) reported by their healthcare provider to CT-
DPH as having LD in the period from January 2000 to Feb-
ruary 2003. Study participants were enrolled prospectively 
(i.e., as each case was identiﬁ  ed, case-patients and controls 
were recruited and enrolled). Letters of invitation were sent 
to potential case-patients after the reporting physician gave 
permission to contact the patient.
Controls were persons 15–70 years of age without LD 
who were matched to the case-patients by age (±5 years 
from case-patient’s birth date) and who had a telephone. 
Controls were identiﬁ  ed by using sequential-digit dialing, 
a technique that uses sequential digits from the end of the 
telephone number of the case-patient to contact potential 
controls (11). This technique also ensured that the case-pa-
tient and control resided in the same general geographic 
area. To maximize the likelihood of contacting control 
study participants, telephone calls were made on noncon-
secutive days, including at least 1 weekend day (during 
daytime and evening hours). For each case-patient, we en-
rolled up to 2 matched controls. Controls were excluded if 
they had had LD 30 days before the diagnosis of LD in the 
matched case-patient (as stated either by them during the 
interview or as documented in their medical record), but 
neither case-patients nor controls were excluded if they had 
had LD in the more distant past, since a previous history of 
the disease was not a contraindication for the vaccine and 
LD can be acquired more than once (12).
Data Collection
Trained  personnel obtained informed consent and 
interviewed both case-patients and controls by telephone 
with a standardized survey. For study participants <18 
years of age, a parent or guardian was interviewed. Case-
patient study participants were interviewed within the year 
of their Lyme diagnosis. Questions concerning demograph-
ics, occupational (forestry or landscaping) and recreational 
risk factors (camping or other outdoor activities), personal 
protective measures (speciﬁ  cally the use of tick repellents 
on the skin or clothing while outdoors; spraying one’s 
property with acaricides; use of protective clothing such as 
long pants, long-sleeved shirts, and light-colored clothing; 
and checking one’s body for ticks after being outdoors) to 
prevent LD were asked of all study participants; for case-
patients, questions about clinical signs and symptoms were 
asked. The questions were phrased to discuss behavior of 
the case-patient before the diagnosis of LD; for control 
study participants, we asked about behavior before the date 
in which their matched case was diagnosed. For example, 
for a case-patient who received a diagnosis in July 2002, 
we asked him or her to respond to the questions on behav-
ior before the LD diagnosis in July 2002: “Do you check 
your body routinely for ticks after outdoor exposure?” For 
the case-patient’s matched control, we asked the same 
question, using the last 12 months before the diagnosis of 
the case as the reference period. Questions are shown in 
Table 1.
The medical records of case-patients and matched con-
trols were reviewed. Information was recorded about re-
ceipt of Lyme vaccine (a case-patient was considered vac-
cinated if at least 1 dose of Lyme vaccine was received >30 
days from the date of the LD diagnosis; for controls, we 
used the dates of the matched case-patient), previous medi-
cal history and, for case-patients, clinical and laboratory 
data at the time of diagnosis. Case-patients and controls 
were excluded from the analysis if their medical records 
could not be obtained.
Classiﬁ  cation of LD 
Case-patients were classiﬁ  ed into 3 categories by 2 in-
vestigators, who were blinded to the case-patient’s name, 
age, source of medical care, vaccination status, and use of 
personal protective measures; disagreements were resolved 
by discussion. The category of deﬁ  nite LD included study 
participants who met the surveillance case deﬁ  nition, i.e., 
erythema migrans (EM) measuring at least 5 cm in diame-
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ter documented by a physician, objective signs of early dis-
seminated disease with a positive test result for antibodies 
against B. burgdorferi (if EM was not present), or objec-
tive signs of late disease with a positive test for antibodies 
against B. burgdorferi (the patient must have had antibod-
ies measured by using the 2-tiered system recommended by 
CDC). The category of possible LD included those study 
participants who met most, but not all, of the criteria in the 
surveillance case deﬁ  nition, such as a case with EM that was 
either <5 cm in diameter or a size that was not documented. 
The third category included those study participants who 
were unlikely to have LD, i.e., they had only nonspeciﬁ  c 
symptoms, such as fatigue, and case-patients with objective 
ﬁ  ndings but with negative serologic test results for LD. In 
addition, we classiﬁ  ed all reported cases of LD according 
to the clinical stage of LD at the time of the diagnosis: early 
localized disease (single EM), early disseminated disease 
(multiple EM, early neurologic disease or cardiac disease), 
or late LD (arthritis or encephalomyelitis).
Statistical Analysis
Matched odds ratios (ORs), associated 95% conﬁ  dence 
intervals (CIs), and their statistical signiﬁ  cance were cal-
culated by using SAS software (SAS Institute, Cary, NC, 
USA). Conditional logistic regression (EGRET Windows; 
CYTEL Corp., Cambridge, MA, USA) was used to adjust 
the matched ORs for the effects of potential confounding 
factors, including sex, use of other personal protective 
measures, receipt of Lyme vaccine, and race. Effectiveness 
was calculated as 1 = the matched OR; p values <0.05 were 
considered signiﬁ  cant.
Results
We identiﬁ   ed 1,436 age-eligible potential case-pa-
tients from January 2000 to February 2003. Thirty-two re-
ported case-patients (2%) were not contacted because the 
reporting physician refused to permit it. Of the remaining 
1,404 case-patients, we were unable to contact 340 (24%). 
Of the 1,064 who were contacted, 195 (18%) refused to 
participate (most refused to give consent to review their 
medical records). We enrolled and interviewed the remain-
ing 869 potential case-patients (82%). Of those enrolled 
in the study, matched controls were not identiﬁ  ed for 78 
(9%), and data were incomplete for 82 (9%) (i.e., medical 
records could not be found). Data presented were part of 
a larger study of the effectiveness of Lyme vaccine. The 
study ended when the Lyme vaccine was withdrawn from 
the market and controls had not yet been obtained for all 
study participants.
Characteristics of the 709 case-patients in the study 
who had at least 1 matched control and the 1,128 matched 
controls are shown in Table 2. The age at the time of infec-
tion ranged from 15 to 70 years (median 48 years). Of the 
709 cases (419 cases had 2 controls and 290 had 1 con-
trol), 467 (66%) were classiﬁ  ed as deﬁ  nite cases of LD, 105 
(15%) as possible cases, and 137 (19%) as unlikely to be 
LD. We found controls were more likely to be female; this 
difference could be explained by our method of identiﬁ  ca-
tion and enrollment of controls (by telephone), if women 
were more likely to be at home at the time of our call. Simi-
lar proportions of case-patients and matched controls had 
received Lyme vaccine.
Tables 3 and 4 show risks factors for and use of personal 
protective measures against LD for case-patients, stratiﬁ  ed 
by certainty of the diagnosis, and their matched controls. Ad-
justment for potential confounding variables such as gender, 
race, receipt of Lyme vaccine, and use of other personal pro-
tective measures was made with conditional logistic regres-
sion. Patients classiﬁ  ed as having either deﬁ  nite or possible 
cases of LD (N = 572) were not signiﬁ  cantly more likely 
to report risk factors for LD than their matched controls (N 
= 898). Deﬁ  nite and possible case-patients were less likely 
than controls to report using protective clothing outdoors 
(46% vs. 58%; adjusted OR 0.6, 95% CI 0.5–0.8; effective-
ness 40%, p<0.0001) and to use tick repellents on their skin 
or clothing (29% vs. 34%, adjusted OR 0.8, 95% CI 0.6–1.0; 
effectiveness 20%, p = 0.05). Spraying acaricides routinely 
on one’s property did not differ signiﬁ  cantly for case-patients 
and matched controls. Estimates did not change signiﬁ  cantly 
when only those cases classiﬁ  ed as deﬁ  nite LD were ana-
lyzed (Table 3).
Recreational outdoor activities, such as hiking and 
camping (85% vs. 83%, p = 0.34), living near heav-
ily wooded or grassy areas (95% vs. 94%, p = 0.18), and 
having pets at home (75% vs. 12%, p = 0.17), were not 
statistically signiﬁ  cantly associated with LD in any of the 
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Table 1. Questions asked in the survey regarding risk factors and personal protective measures 
Do you (your child) live in close proximity to grassy fields or heavily wooded areas? 
Do you (your child) have an occupational exposure that puts you at risk for tick bites (such as working in landscaping, forestry, 
farming, or wild-life parks management)? 
Do you (your child) engage in outdoor activities that put you at higher risk for tick bites (such as hiking, camping, gardening, hunting)?  
Do you (your child) wear clothing to protect against ticks while outdoors, e.g., long pants, long-sleeved shirts, or light-colored clothing? 
Do you (your child) routinely use tick repellents on the skin and/or clothing while outdoors? 
Do you routinely spray acaricides against ticks on your property? 
Do you (your child) routinely check for ticks on the body after being outdoors?  
Do you have any pets at home? Personal Protective Measures to Prevent Lyme Disease
groups. Only among groups in which the case-patient was 
classiﬁ  ed as unlikely to have LD were patients signiﬁ  cantly 
more likely than matched controls to have an occupational 
risk factor for LD such as forestry or landscaping (28% vs. 
12%, adjusted OR 3.1, 95% CI 1.6–5.9, p = 0.0007). None 
of the personal protective measures was effective in groups 
classiﬁ  ed as unlikely to have LD.
We also analyzed the data excluding all controls with 
a previous history of LD, and the results were virtually un-
changed except that having an occupational exposure was a 
risk factor. When we excluded controls who had previously 
had LD from the analysis, case-patients were more likely to 
have an occupational exposure than were matched controls; 
this was true for deﬁ  nite cases of LD (60 [15%] of cases vs. 
51 [9%] of controls; OR 1.5, 95% CI 0.9–2.4, p = 0.05), 
for deﬁ  nite cases and possible cases (78 [16%] of cases vs. 
69 [10%] of controls; OR 1.5, 95% CI 1.03–2.2, p = 0.03), 
and for unlikely cases (34 [28%] of cases vs. 16 [9%] of 
controls; OR 3.6, 95% CI 1.8–7.7, p = 0.0006).
Discussion
This is the ﬁ  rst study, to our knowledge, to demon-
strate that any personal protective measure against LD is 
effective. Use of protective clothing while outdoors was 
40% effective in strata with case-patients classiﬁ  ed as hav-
ing deﬁ  nite or possible LD. Of note, this strategy was not 
signiﬁ  cantly effective in strata with case-patients classiﬁ  ed 
as unlikely to have LD (not only were the differences be-
tween patients and controls in this group not statistically 
signiﬁ  cant, but the magnitude of the effect was much di-
minished), which supports the validity of the results (13). 
The use of tick repellents on the skin or clothing while 
outdoors was also effective (effectiveness of 20%) for pre-
venting LD.
By contrast, inspecting one’s body for and removing 
ticks was not found to be an effective strategy to prevent 
LD nor was using acaricides on one’s property. A potential 
limitation of the study is that use of the protective measures 
was based on self-report, so these practices could neither be 
conﬁ  rmed nor quantiﬁ  ed. Undoubtedly, there is variability 
in the practice of these personal protective measures that 
was not ascertained by the study. For example, some per-
sons may only perform cursory tick checks, while others 
may engage in a more careful examination. Similarly, there 
may be variability in the application of tick repellents—in 
the amount and frequency of application and whether the 
repellents were applied to clothing, to exposed skin, or to 
both, as well as variations in repellents themselves. (Active 
ingredients such as DEET [N,N-diethyl-3-methyltolua-
mide], permethrin, or natural or herbal repellents and their 
concentrations may vary.) Whether rigorous practice of 
these protective measures might be protective is unknown. 
Furthermore, we did not assess for ecologic differences 
that may have played a role in the possibility for household 
acaricides to have been effective or for risk factors for the 
disease, such as apartment versus single family dwelling. 
The effectiveness of the use of acaricides may also possibly 
rely on routine use not only by the study participant but 
also by close neighbors. 
We used sequential-digit technique, which ensures 
that controls are generated from the same general area. We 
did not analyze differences in locations within telephone 
exchanges; however, LD is considered to be endemic in the 
entire state of Connecticut, and no major differences would 
be expected within areas of a telephone exchange. Another 
potential limitation of our study is recall bias—study par-
ticipants are more likely to remember things related to LD 
if they have had the disease itself.
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Table 2. Characteristics of Lyme disease study participants, Connecticut, July 2000 through February 2003 
Characteristics Case-patients (N = 709), no. (%) Controls (N = 1,128), no. (%) p value
Age, y
 Median 48 49 0.71
 Mean 46 47
 Range 15–70 15–70
Sex
  Female 376 (53) 715 (63) <0.001
  Male 333 (47) 413 (37)
Race
  Caucasian 689 (97) 1094 (97) 0.66
 African  American 3 8
 Hispanic 4 6
 Other 13 14
Underlying medical problems other than 
Lyme disease (e.g., diabetes, asthma)
298 (42) 508 (45) 0.19
Had Lyme disease* 110 (17) 143 (14) 0.095
Received Lyme vaccine† 44 (6) 73 (6) 0.82
*Having Lyme disease was defined as the following: for case-patients, having Lyme disease at a time other than the episode for which a case-patient was 
enrolled in the study; for controls, having Lyme disease at a time other than the focal time of disease for the case-patient. 
†A study participant was considered vaccinated if he or she received at least 1 dose of Lyme vaccine. RESEARCH
The  ﬁ  nding that occupational exposure did not ap-
pear to be a risk factor for cases classiﬁ  ed as deﬁ  nite or 
possible LD suggests that most of the case-patients with 
true LD reported in Connecticut acquired their LD from 
periresidential or recreational exposure. However, when 
we excluded controls with a history of LD in the past, oc-
cupational exposure was a risk factor for the disease. The 
ﬁ  nding that case-patients classiﬁ  ed as unlikely to have LD 
were more likely to have had occupational exposures than 
the corresponding controls is somewhat perplexing. Pos-
sibly persons who are in occupations that have been as-
sociated with LD and who are aware of their potential risk 
for the disease are more likely to seek medical attention 
for suspected LD symptoms, and their physicians may 
be more likely to report them as LD cases because of the 
perceived occupational risk. Such a diagnostic bias would 
tend to artiﬁ  cially elevate the prevalence of occupational 
exposure among these persons suspected to have LD who 
in fact probably do not have LD. It is also possible that oc-
cupational exposure is a true risk factor for the other condi-
tions that are causing symptoms in these persons who are 
unlikely to have LD.
Public health strategies are important in the control of 
LD, an emerging infection with continually increasing inci-
dence (1); nonetheless, the implementation and assessment 
of these strategies have proven to be challenging. Public 
health ofﬁ  cials must take into account not only the effec-
tiveness of the public health strategy, but also the level of 
engagement of those who are supposed to follow the rec-
ommendations (14). Although this study indicates that use 
of protective clothing and the use of tick repellents on the 
skin or clothing while outdoors are effective, clearly not all 
persons at risk follow these recommendations. Our results 
provide data to support recommendations that have been 
in place for many years. By no means should our results 
be taken as recommendations to cease personal protective 
measures that have been recommended by public health of-
ﬁ  cials but that we found not to be effective. Although our 
study included adolescents, most study participants were 
adults; therefore, whether these ﬁ  ndings apply to children, 
a group at high risk of acquiring LD, is not known.
Additional educational efforts about these practices, 
targeted at persons living in LD-endemic areas, may be 
beneﬁ  cial. The use of protective clothing may be impor-
tant for preventing not only LD but also other tick-borne 
infections. Nevertheless, these strategies, even used opti-
mally, are likely to prevent only a portion of cases of LD. 
Other strategies, such as improved vaccines and measures 
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Table 3. Personal protective measures and risk factors for Lyme disease, Connecticut, July 2000 through February 2003 
Personal protective measures Case-patients, no. (%) Matched controls, no. (%) Odds ratio* (95% CI)† p value
Use of protective clothing while outdoors
 Definite 215  (46) 
N = 467
427 (59)  
N = 724
0.6 (0.5–0.7)  <0.0001
  Definite and possible 265 (46)  
N = 572
524 (58)  
N = 898
0.6 (0.5–0.8)  <0.0001
 Unlikely 72  (53)
N = 137
121 (53)  
N = 230
0.9 (0.6- 1.3) 0.55
Use of tick repellents on skin or clothing while outdoors
  Definite 138 (30)  
N = 467
252 (35) 
N = 724
0.8 (0.6–0.9)  0.04
  Definite and possible 168 (29)  
N = 570
303 (34) 
N = 890
0.8 (0.6–0.99) 0.0499
 Unlikely 37  (27) 
N = 136
64 (28) 
N = 228
0.9 (0.6–1.5) 0.83
Spraying property with tick acaricides
 Definite 16  (7)
N = 237
52 (11)
N = 467
0.6 (0.3–1.1) 0.09
  Definite and possible 19 (7)
N = 285
62 (11)
N = 557
0.6 (0.3–1.0) 0.06
 Unlikely 3  (8) 
N = 36
16 (12)
N = 133
0.7 (0.2–3.0) 0.61
Checking the body for ticks after exposure
  Definite 360 (77)  
N = 467
560 (77)  
N = 724
1.1 (0.8–1.4)  0.64
  Definite and possible 443 (77)  
N = 572
703 (78)  
N = 898
1.0 (0.8–1.4)  0.81
  Unlikely 107 (78)  
N = 137
181 (79)
N = 230
0.9 (0.5–1.5)  0.61
*All estimates were adjusted for possible confounders (sex, race, receipt of Lyme vaccine, and use of other personal protective measures) with 
conditional logistic regression. 
†CI, confidence interval. Personal Protective Measures to Prevent Lyme Disease
to reduce tick abundance in areas where human exposure to 
ticks is high, should continue to be pursued.
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0.9 (0.3–2.6)  0.89
Having pets at home
  Definite   283 (73)  
N = 386 
488 (72)  
N = 681 
1.2 (0.9–1.7)  0.17
  Definite and possible 355 (75)  
N = 472 
599 (71)  
N = 838 
1.2 (0.9–1.6)  0.17
 Unlikely 81  (77)
N = 105 
151 (72)  
N = 210 
1.4 (0.8–2.6)  0.27
*All estimates were adjusted for possible confounders (sex, race, receipt of Lyme vaccine, and use of other personal protective measures) with 
conditional logistic regression. 
†CI, confidence interval. RESEARCH
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ATTENTION EID READERS: 
MAKE YOUR PLANS TO ATTEND CDC’s 
6TH INTERNATIONAL 
CONFERENCE ON EMERGING 
INFECTIOUS DISEASES
MARCH 16-19 2008, 
HYATT REGENCY ATLANTA GEORGIA
•  Registration for ICEID 2008 is 
now open! 
• Go  to  www..iceid.org and follow the links 
to register online or to download the regis-
tration form for ICEID 2008. 
• Pre-registration  Deadline: 
February 28, 2008
•  Pre-registration $400.00 (Onsite $450.00) 
•  Student Pre-registration $200.00 (Student 
Onsite $250.00)
•  Student registration is limited to 300 
spaces. Documentation of current 
enrollment status must accompany form.
PLEASE VISIT THE ICEID WEBSITE TO 
SEE THE LATEST UPDATE OF THE 
PROGRAM, INCLUDING KEYNOTE 
SPEAKERS, PLENARIES 
AND INVITED PANELS.